The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Obesity causes insulin resistance by increasing activation of the sympathetic nervous system and the release of the stress hormone norepinephrine, according to a new study.

the annual meeting of The Obesity Society. The first abstract comprises outcomes data from Allurion’s largest real-world cohort on record. The data, gathered from 19,428 patients across 72 ...

The RESPOND trial adapted to COVID-19 disruptions by shifting to a cluster-parallel randomized design, enabling analysis ...

The World Health Organization describes obesity as an epidemic that disrupts metabolic equilibrium ... Systematic literature ...

Obesity has reached epidemic proportions across the globe ... Pennington Biomedical has the vision to lead the world in promoting metabolic health and eliminating metabolic disease through ...

Despite any potential detriments, demand in the civilian world for weight ... obese populations across the country. In 2022, all U.S. states and territories reported an obesity prevalence of ...

A global “stroke epidemic” is looming - growing rates of diabetes and obesity across the world coupled with lack of exercise have led to the number of strokes afflicting people aged between 20 ...

The Independent is trusted by 27 million Americans from across the entire political ... and Lilly will examine the “real-world effectiveness” of anti-obesity treatment Mounjaro, also known ...

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2024, the annual meeting of The Obesity Society.